MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clin Mol Hepatol. 2022;28(2):150-163.   Published online 2021 Nov 10     DOI: https://doi.org/10.3350/cmh.2021.0310
Citations to this article as recorded by Crossref logo
Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists?
Chi-Ho Lee
Primary Care Diabetes.2022;[Epub]     CrossRef
Atherosclerotic cardiovascular disease in non‐metabolic nonalcoholic fatty liver disease
Tsubasa Tsutsumi, Takumi Kawaguchi, Dan Nakano, Takuji Torimura
Hepatology Research.2022; 52(3): 317.     CrossRef
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura
Clinical and Molecular Hepatology.2022; 28(2): 269.     CrossRef
MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups
Hyoeun Kim, Chan Joo Lee, Sang Hoon Ahn, Kwan Sik Lee, Byoung Kwon Lee, Su Jung Baik, Seung Up Kim, Jung Il Lee
Digestive Diseases and Sciences.2022; 67(10): 4919.     CrossRef
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis
Shuhei Fukunaga, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi, Mohammed Eslam, Shinobu Yoshinaga, Hirohiko Abe, Ryuichi Nouno, Seiya Joh, Keiichi Mitsuyama, Jacob George, Takuji Torimura
Hepatology Research.2022; 52(8): 699.     CrossRef
Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients
Susumu Inamine, Masayoshi Kage, Jun Akiba, Takumi Kawaguchi, Sachiyo Yoshio, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Ryuki Hashida, Kouichi Oshiro
Hepatology Research.2022; 52(10): 841.     CrossRef
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro
Hepatology Research.2022;[Epub]     CrossRef
MAFLD, patient-centred care, and APASL
Shiv K. Sarin, Mohammed Eslam, Jian-Gao Fan, Han-Chieh Lin, Jacob George, Masao Omata
Hepatology International.2022; 16(5): 1032.     CrossRef
The relationship between metabolic dysfunction‐associated fatty liver disease and low muscle mass in an asymptomatic Korean population
Ji Yeon Seo, Eun Ju Cho, Min Joo Kim, Min‐Sun Kwak, Jong In Yang, Su Jin Chung, Jeong Yoon Yim, Ji Won Yoon, Goh Eun Chung
Journal of Cachexia, Sarcopenia and Muscle.2022;[Epub]     CrossRef
MAFLD : A quick fact check
Nahum Méndez‐Sánchez, Jian‐Gao Fan, Mohamed El‐Kassas, Marcos Girala
Liver International.2022; 42(12): 2903.     CrossRef
Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years
In-Ho Seo, Hye Sun Lee, Yong-Jae Lee
Cardiovascular Diabetology.2022;[Epub]     CrossRef